On February 28, Trauer Bio released an earnings forecast with its net profit attributable to shareholders of the listed company amounting to $5.2272 million to $5.8608 million, down 60% to 64% year-on-year.
On February 28, Trauer Bio released an earnings forecast with its net profit attributable to shareholders of the listed company amounting to $5.2272 million to $5.8608 million, down 60% to 64% year-on-year.
The operating revenue of Trauer Bio for FY2021 decreased by approximately $10.1376 million compared to the same period of the previous year. Among them, its revenue from sales of skincare products decreased by approximately $7,286,400, or approximately 43% year-on-year. Its revenue from sales of medical devices decreased by approximately $2.8512 million, approximately decreased 9% year-on-year, compared with the same period of the previous year.
The forecast stated that the decrease in its revenue was mainly due to the impact of marketing strategy adjustments and staff changes in the marketing department relocation. As the company reduced the number of times live streaming of skincare products in 2021 and also reduced the investment in expenses for product sales platform station promotion. Although the company significantly increased the investment in promotion expenses for the company’s product brands, the investment in brand expenses did not show a promotional effect in the short term.
In terms of profit, due to the increase in brand promotion expenses and R&D expenses, coupled with the decline in operating income, gross profit decreased by between $8,236,800 to $8,395,200 compared to the same period of the previous year. Moreover, the company’s marketing strategy adjustment and hiring of professional marketing agencies to improve the company’s overall marketing plan increased brand promotion expenses by $1,615,700. At the same time, the company attaches importance to R&D activities and continues to increase its R&D investment with R&D expenses increasing by approximately $601,900 compared to the same period of the previous year representing a year-on-year increase of approximately 20%.
It is noteworthy that on January 4, Trauer Bio announced that the company filed a public offering of shares to unspecified qualified investors and listed on the Beijng Stock Exchange at the Guangdong Securities Regulatory Bureau on January 4, 2022, which means that Trauer Bio plan to list on the Beijng Stock Exchange. And just on December 24, 2021, Trauer Bio and CITIC Securities, the sponsor, submitted the withdrawal of the application for listing on the NSE and withdrew the registration application documents voluntarily.
Trauer Bio achieved its revenue of $34 million and a net income of $10.6358 million in 2018. Its revenue reached $48 million and a net income of $11.3875 million in 2019. Its revenue reached $48 million and its net income was $14.5459 million in 2020.
